title: Administration of human platelet-rich plasma reduces infarction volume and improves motor function in adult rats with focal ischemic stroke.
abstract: Platelet-rich plasma (PRP) is a milieu of bioactive factors, including platelet derived growth factor, transforming growth factor beta, among many others. Despite accumulating evidence on PRP's safety and efficacy for treating musculoskeletal injuries, limited studies have been performed using PRP in brain disorders. This study aimed to explore the potential benefits of administration of human PRP lysate after ischemic stroke in rats. An ischemic stroke model was generated by occlusion of the right middle cerebral artery, then 90 min later, stroke rats were randomly assigned to receive local infusion to the ischemic area of human PRP lysate, human albumin solution (HSA), saline or no treatment at all. An additional group of stroke rats received systemic infusion of human PRP lysate to further assess the therapeutic effects of this treatment. Results showed that while local infusion of HSA or saline, and systemic administration of human PRP lysate, compared to no treatment significantly reduced infarct volume (37.4%, 40.1%, and 39.9% vs 49.7%) and neurological deficit score (2.2, 2.6, and 2.8 vs 3.7), the greatest neuroprotection (31.0% infarct volume and 1.6 neurological deficit score) was found in stroke animals that received local intra-arterial infusion of human PRP lysate (p's<0.05). In conclusion, administration of human PRP attenuates brain injury after focal ischemia. Our results suggest PRP should be investigated further as a potential point-of-care biomaterial following stroke.
authors.affiliation: Institute of Hypoxia Medicine, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; Beijing Institute for Brain Disorders, Capital Medical University, Beijing 100069, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Institute of Hypoxia Medicine, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; Beijing Institute for Brain Disorders, Capital Medical University, Beijing 100069, China.
authors.forename: Guomin
authors.initials: G
authors.lastname: Ying
authors.affiliation: Institute of Hypoxia Medicine, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; Beijing Institute for Brain Disorders, Capital Medical University, Beijing 100069, China.
authors.forename: Changhong
authors.initials: C
authors.lastname: Ren
authors.affiliation: Brownell-Talbot School, Omaha, NE, USA.
authors.forename: Yunneng
authors.initials: Y
authors.lastname: Jizhang
authors.affiliation: Department of Neurosurgery, Wayne State University School of Medicine, Detroit, MI, USA.
authors.forename: David
authors.initials: D
authors.lastname: Brogan
authors.affiliation: Institute of Hypoxia Medicine, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; Beijing Institute for Brain Disorders, Capital Medical University, Beijing 100069, China.
authors.forename: Zongjian
authors.initials: Z
authors.lastname: Liu
authors.affiliation: Institute of Hypoxia Medicine, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; Beijing Institute for Brain Disorders, Capital Medical University, Beijing 100069, China.
authors.forename: Sijie
authors.initials: S
authors.lastname: Li
authors.affiliation: Department of Neurosurgery, Wayne State University School of Medicine, Detroit, MI, USA.
authors.forename: Yuchuan
authors.initials: Y
authors.lastname: Ding
authors.affiliation: Department of Neurosurgery and Brain Repair, University of South Florida, Tampa, FL, USA.
authors.forename: Cesar V
authors.initials: CV
authors.lastname: Borlongan
authors.affiliation: Department of Vascular Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China. Electronic address: zhangyzh@public3.bta.net.cn.
authors.forename: Jian
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Institute of Hypoxia Medicine, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; Beijing Institute for Brain Disorders, Capital Medical University, Beijing 100069, China; Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China. Electronic address: jixm@ccmu.edu.cn.
authors.forename: Xunming
authors.initials: X
authors.lastname: Ji
mesh_terms: D000818:Animals; D002544:Cerebral Infarction / Q000473:pathology*; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D008297:Male; D018696:Neuroprotective Agents / Q000494:pharmacology*; D053657:Platelet-Rich Plasma; D051381:Rats; D017207:Rats, Sprague-Dawley; D020127:Recovery of Function / Q000187:drug effects*; D020521:Stroke / Q000473:pathology
chemical_list: D018696:Neuroprotective Agents
keywords: Albumin; Biomaterials; Neuroprotection; Platelets; Stroke; Therapeutics